Literature DB >> 17356384

Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.

Cornelius Courts1, Manuel Montesinos-Rongen, Jose Ignacio Martin-Subero, Anna Brunn, Dörte Siemer, Reina Zühlke-Jenisch, Hendrik Pels, Annika Jürgens, Uwe Schlegel, Ingo G H Schmidt-Wolf, Carlo Schaller, Guido Reifenberger, Michael Sabel, Ute Warnecke-Eberz, Otmar D Wiestler, Ralf Küppers, Reiner Siebert, Martina Deckert.   

Abstract

Recent studies point to a role of nuclear factor (NF)-kappaB signaling in a subset of diffuse large B cell lymphomas. We have analyzed the expression of 21 genes encoding NF-kappaB family members, upstream modulators, and targets in 32 primary central nervous system lymphomas (PCNSLs) by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Compared with nonmalignant germinal center centroblasts, expression of BCL10, REL, IAP1, and TRAF1 was significantly lower in PCNSLs, whereas that of BAX, BCLXL, BCL2, MALT1, CARD9, CARD10, CARD11, CARD14, CCND2, cFLIP, RELA, RELB, NFKB1, NFKB2, and IRF4 was higher. Hierarchical clustering of gene expression data revealed two distinct subgroups of PCNSLs, which were characterized by significantly different transcriptional levels, predominantly of BCL10, but also of REL and IAP1. Thus, these quantitative RT-PCR data with expression of genes of the NF-kappaB family as well as NF-kappaB-regulated genes together with immunohistochemical detection of nuclear RELA and REL indicate activation of the NF-kappaB pathway in PCNSLs, which may contribute to their high proliferative activity and the low level of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356384     DOI: 10.1097/01.jnen.0000248553.45456.96

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  13 in total

1.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 2.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

3.  Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Ariz Akhter; Noraidah Masir; Ghaleb Elyamany; Kean-Chang Phang; Etienne Mahe; Ali Matar Al-Zahrani; Meer-Taher Shabani-Rad; Douglas Allan Stewart; Adnan Mansoor
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

4.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

Authors:  I Vater; M Montesinos-Rongen; M Schlesner; A Haake; F Purschke; R Sprute; N Mettenmeyer; I Nazzal; I Nagel; J Gutwein; J Richter; I Buchhalter; R B Russell; O D Wiestler; R Eils; M Deckert; R Siebert
Journal:  Leukemia       Date:  2014-09-05       Impact factor: 11.528

5.  PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.

Authors:  James Godfrey; Sravya Tumuluru; Riyue Bao; Michael Leukam; Girish Venkataraman; John Phillip; Carrie Fitzpatrick; James McElherne; Brendan W MacNabb; Robert Orlowski; Sonali M Smith; Justin Kline
Journal:  Blood       Date:  2019-03-25       Impact factor: 22.113

6.  Nuclear factor-κB activation in primary lymphoma of bone.

Authors:  Lianne Koens; Fenna H Heyning; Agota Szepesi; András Matolcsy; Pancras C W Hogendoorn; Patty M Jansen
Journal:  Virchows Arch       Date:  2013-01-19       Impact factor: 4.064

7.  Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell.

Authors:  M Montesinos-Rongen; A Brunn; S Bentink; K Basso; W K Lim; W Klapper; C Schaller; G Reifenberger; J Rubenstein; O D Wiestler; R Spang; R Dalla-Favera; R Siebert; M Deckert
Journal:  Leukemia       Date:  2007-11-08       Impact factor: 11.528

8.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

Review 9.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

10.  Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma.

Authors:  Tobias Birnbaum; Sigrid Langer; Sigrun Roeber; Louisa von Baumgarten; Andreas Straube
Journal:  Neurol Int       Date:  2013-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.